Movement Alert｜AKESO Falls 6.32% in Regular Trading, Profit-Taking After H1 Results Still Show Loss Despite 28% Revenue Growth

Market Focus08-28 09:31

On August 28, AKESO fell 6.32% in regular trading, trading at 92.55 HKD/share, with turnover of HKD 188 million. The decline came after the company reported interim results showing continued losses, triggering profit-taking following a 14% rally over the prior two trading days.

AKESO posted H1 revenue of RMB 1.806 billion, up 27.92% year-over-year, driven by commercial sales of RMB 1.803 billion (+28.65%). The attributable loss narrowed 24% to RMB 447 million from RMB 570 million a year earlier, with loss per share at RMB 0.46 versus RMB 0.64 previously. Operating cash flow turned positive at approximately RMB 290 million, and sales expense ratio improved to 43.56% from 47.80%.

The stock had surged over 14% across August 26-27 after ivonescimab achieved the primary OS endpoint in a Phase 3 biliary tract cancer trial and ahead of earnings release. Despite improving fundamentals, the company remains unprofitable, prompting investors to lock in gains after the catalysts materialized.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111340850?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111340850","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AKESO Falls 6.32% in Regular Trading, Profit-Taking After H1 Results Still Show Loss Despite 28% Revenue Growth","media":"Market Focus","content":"<p><p>On August 28, AKESO fell 6.32% in regular trading, trading at 92.55 HKD/share, with turnover of HKD 188 million. The decline came after the company reported interim results showing continued losses, triggering profit-taking following a 14% rally over the prior two trading days.</p><p>AKESO posted H1 revenue of RMB 1.806 billion, up 27.92% year-over-year, driven by commercial sales of RMB 1.803 billion (+28.65%). The attributable loss narrowed 24% to RMB 447 million from RMB 570 million a year earlier, with loss per share at RMB 0.46 versus RMB 0.64 previously. Operating cash flow turned positive at approximately RMB 290 million, and sales expense ratio improved to 43.56% from 47.80%.</p><p>The stock had surged over 14% across August 26-27 after ivonescimab achieved the primary OS endpoint in a Phase 3 biliary tract cancer trial and ahead of earnings release. Despite improving fundamentals, the company remains unprofitable, prompting investors to lock in gains after the catalysts materialized.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Falls 6.32% in Regular Trading, Profit-Taking After H1 Results Still Show Loss Despite 28% Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Falls 6.32% in Regular Trading, Profit-Taking After H1 Results Still Show Loss Despite 28% Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-28 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 28, AKESO fell 6.32% in regular trading, trading at 92.55 HKD/share, with turnover of HKD 188 million. The decline came after the company reported interim results showing continued losses, triggering profit-taking following a 14% rally over the prior two trading days.</p><p>AKESO posted H1 revenue of RMB 1.806 billion, up 27.92% year-over-year, driven by commercial sales of RMB 1.803 billion (+28.65%). The attributable loss narrowed 24% to RMB 447 million from RMB 570 million a year earlier, with loss per share at RMB 0.46 versus RMB 0.64 previously. Operating cash flow turned positive at approximately RMB 290 million, and sales expense ratio improved to 43.56% from 47.80%.</p><p>The stock had surged over 14% across August 26-27 after ivonescimab achieved the primary OS endpoint in a Phase 3 biliary tract cancer trial and ahead of earnings release. Despite improving fundamentals, the company remains unprofitable, prompting investors to lock in gains after the catalysts materialized.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1111340850","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111340850","pubTimestamp":1787880718,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 28, AKESO fell 6.32% in regular trading, trading at 92.55 HKD/share, with turnover of HKD 188 million. The decline came after the company reported interim results showing continued losses,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势警报|AKESO 常规交易下跌 6.32%，尽管收入增长 28%，上半年业绩仍显示亏损后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On August 28, AKESO fell 6.32% in regular trading, trading at 92.55 HKD/share, with turnover of HKD 188 million. The decline came after the company reported interim results showing continued losses, triggering profit-taking following a 14% rally over the prior two trading days.AKESO posted H1 revenue of RMB 1.806 billion, up 27.92% year-over-year, driven by commercial sales of RMB 1.803 billion (+28.65%). The attributable loss narrowed 24% to RMB 447 million from RMB 570 million a year earlier, with loss per share at RMB 0.46 versus RMB 0.64 previously. Operating cash flow turned positive at approximately RMB 290 million, and sales expense ratio improved to 43.56% from 47.80%.The stock had surged over 14% across August 26-27 after ivonescimab achieved the primary OS endpoint in a Phase 3 biliary tract cancer trial and ahead of earnings release. Despite improving fundamentals, the company remains unprofitable, prompting investors to lock in gains after the catalysts materialized.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111340850","isCrawlerRequest":true}